dr bennett's semaglutide Frequently Asked Questions 2024, GLP-1 FAQs with Dr. Bryce Peterson Preventative semaglutide and tirzepatide treatment

The mechanism of action has been determined that KPV inhibits the activation of NF-kappaB and MAP kinase inflammatory signaling pathways, and reduces pro-inflammatory cytokine secretionacts via PepT1 expressed in immune and intestinal epithelial cells..[and] reduces the incidence of DSS- and TNBS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression (Dalmasso et al., 2008)

But that same process creates a problem

Providers should weigh metabolic benefits against potential IBD-related risks on an individual basis

You can find more details in our Best Practices for Peptide Storage & Handling and Peptide Storage Stability Guidelines

This personalized approach is a core part of the modern treatment of obesity